Analysis on metabolites with small molecule of serum in bone marrow suppression model mice with metabolomics method

doi:10.3724/SP.J.1123.2017.08003

Abstract

Abstract:

Bone marrow suppression is a common symptom in patients with malignant tumor after chemotherapy. Studying the changes of metabolites caused by bone marrow depression can provide insights for the diagnosis of bone marrow suppression disease and for the development of drug therapy. Male BalB/C mice were injected with cyclophosphamide to establish a bone marrow suppression model. Gas chromatography-mass spectrometry (GC-MS) with fingerprinting was used to analyze the normal and model mice blood metabolites. Principal component analysis and orthogonal to partial least squares discriminant analysis (OPLS-DA) on metabolomics for data multidimensional statistical analysis was also used. Compared to the normal group in terms of the metabolic profile of bone marrow suppression mice, there were 15 endogenous metabolites in mouse plasma, nine of which were statistically significantly different, including glucose-1-phosphate, 4-nitrophenol, acetanilide, cortisone, nicotinamide, loganin, caffeic acid, linoleic acid and oleic acid (P<0.05). These results indicate that metabolite can be used as an important marker in bone marrow suppression, which can help to reveal the pathogenesis of bone marrow suppression induced by chemotherapy and determine the disease development stage and the effectiveness of follow-up treatment.

Key words: gas chromatography-mass spectrometry (GC-MS), marrow suppression, metabolomics, mouse, small molecule

CLC Number:

O658

CHEN Jing, LIU Yunxia, XU Yefeng, WANG Yiqing. Analysis on metabolites with small molecule of serum in bone marrow suppression model mice with metabolomics method[J]. Chinese Journal of Chromatography, 2017, 35(12): 1312-1316.

References

[1] Yerebakan C, Kaminski A, Westphal B, et al. J Thorac Cardiovasc Surg, 2011, 142(6):1530
[2] Xu S J, Du J, Teng Z, et al. Modern Oncology, 2016, 24(9):1337许世娟, 杜娟, 滕志, 等. 现代肿瘤医学, 2016, 24(9):1337
[3] Yang P Y, Li X J, Liu H G, et al. Drug & Clinic, 2016, 31(6):747杨佩颖, 李小江, 刘宏根, 等. 现代药物与临床, 2016, 31(6):747
[4] Yang Y G. Chronic Pathematology Journal, 2017(6):649杨逸淦. 慢性病学杂志, 2017(6):649
[5] Iwanuma Y, Chen F-A, Egilmez N K, et al. Cancer Res, 1997, 57(14):2937
[6] Chen Y, Zhang J, Lei G, et al. Oncotarget, 2016, 7(52):87496
[7] He W, Miao F J P, Lin D C H, et al. Nature, 2004, 429(6988):188
[8] Fan Z J, Tian Y Q, Liu B Y, et al. Acta Nutrimenta Sinica, 2015, 37(1):96范志娟, 田亚琼, 刘宝阳, 等. 营养学报, 2015, 37(1):96
[9] Bertram H C, Larsen L B, Chen X, et al. J Agric Food Chem, 2012, 60(2):676
[10] Chakrabarti G, Silvers M A, Ilcheva M, et al. Sci Rep, 2015(5):17066
[11] Kim K, Kong S-Y, Fulciniti M, et al. Br J Haematol, 2010, 149(4):537
[12] Airiau K, Prouzet-Mauléon V, Rousseau B, et al. Oncotarget, 2016, 7(1):845
[13] Moser H W, Moser A B, Smith K D, et al. J Inherit Metab Dis, 1992, 15(4):645
[14] Jindal N, Banik A, Prabhakar S, et al. J Cell Biochem, 2016, 118(7):1699
[15] Xu L, Cao Y. BMC Complement Altern Med, 2016, 16(1):511
[16] Bülter T, Elling L. Glycoconjugate J, 1999, 16(2):147
[17] Vandamme E J, Loo J V, Machtelinckx L, et al. Adv Appl Microbiol, 1987, 32(6):163
[18] Stark F C, McCluskie M J, Krishnan L. Vaccines, 2016, 4(4):44
[19] Shigeto K, Takashi K, Masaru K, et al. EP Patent, 0305981, 1989-09-02
[20] Karim K, Gupta S K. Biodegradation, 2002, 13(5):353
[21] De Palo E F, Antonelli G, Benetazzo A, et al. Clin Chim Acta, 2009, 405(1):60
[22] Bobbert P, Kühl U, Poller W, et al. J Card Fai, 2015, 21(4):330
[23] Cetkovic-Cvrlje M, Sandler S, Eizirik D L. Endocrinology, 1993, 133(4):1739
[24] Jia M Q, Xue Y, Wang Y, et al. Journal of Instrumental Analysis, 2016, 35(2):172贾孟琪, 薛芸, 王彦, 等. 分析测试学报, 2016, 35(2):172
[25] Brown D M, Williams H, Ryan K J P, et al. Sci Rep, 2016(6):28693